Teaching Medical Devices to Understand the “Ionic Language” of Cells: Bioiontronics Moves Toward Closed-Loop Medicine

The human body does not rely solely on nerve impulses to transmit information. Changes in the concentrations of ions such as sodium, potassium, and calcium, together with neurotransmitters and proteins, also continuously regulate cellular activity. A review published in *Nature Reviews Bioengineering* notes that “bioiontronics” is seeking to enable medical devices to directly read and write this chemical language, laying the technological foundation for devices that can sense biomarkers and then respond autonomously.

Traditional bioelectronic devices generally convert tissue activity into electronic signals. While well suited to recording overall electrical potentials, they may not be able to distinguish which ion or molecule a signal originates from. Bioiontronic components use materials such as selective membranes, nanopores, and hydrogels to control particle transport, potentially enabling them to identify electrolyte imbalances, neurotransmitters, or specific protein markers and convert the results into processable outputs.

Their core physical processes include diffusion, electric-field-driven migration, selective transport within nanochannels, and interfacial electrical double-layer and pseudocapacitive effects. These mechanisms can also be used in reverse: after detecting an abnormality, a device can locally deliver ions, drugs, or signaling molecules, creating a closed loop of “sensing—interpretation—intervention” rather than merely sending data outside the body for human interpretation.

Researchers have therefore envisioned a range of potential uses, from personalized diagnostics and modulation of neural activity to implantable treatments triggered by biomarkers. Another approach is “droplet electronics,” in which tiny hydrogel droplets are assembled into soft networks containing different functional modules. Such structures more closely resemble the hydrated, soft environment of tissues and may help reduce device size and improve biocompatibility.

However, the maturity of these technologies varies. Some nanopore-based molecular-reading technologies have already been commercialized, such as DNA sequencing, while ionic devices that deliver therapeutic substances to specific sites mostly remain at the preclinical research stage. Moving from a functional prototype to a long-term implant still requires answers to questions such as whether materials provoke foreign-body reactions, whether packaging can withstand bodily fluids, and whether component performance drifts over time.

More challenging still, signals in physiological environments often overlap. A change in the concentration of the same ion may occur in different diseases or during normal regulatory processes, and multiple molecules may cross a sensing interface simultaneously. If a device is to decide autonomously when to provide treatment, it must not only improve selectivity but also establish reliable multimodal interpretation methods to avoid mistaking noise or normal fluctuations for pathological signals.

This review therefore presents not a single therapy about to reach the market, but a medical-device architecture that is still taking shape. Only if bioiontronics can integrate precise sensing, localized delivery, and safe control on a miniaturized platform might medical devices evolve from passive recorders into autonomous systems capable of responding to the body’s condition. Until then, their clinical value must be progressively validated through long-term animal studies, manufacturing consistency, and human trials.